目的 探討潤燥止癢膠囊聯(lián)合鹽酸奧洛他定片治療慢性蕁麻疹的臨床療效。方法 選取中國人民解放軍第一九五醫(yī)院2017年2月-2017年8月收治的慢性蕁麻疹患者84例，隨機(jī)分成對照組和治療組，每組各42例。對照組口服鹽酸奧洛他定片，5 mg/次，2次/d；治療組在對照組基礎(chǔ)上口服潤燥止癢膠囊，2 g/次，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀評分和DLQI評分及血清學(xué)指標(biāo)改善情況。結(jié)果 治療后，對照組臨床總有效率為78.57%，顯著低于治療組的95.24%。兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組臨床癥狀和DLQI評分均顯著降低，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組比對照組降低的更明顯，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者血清IL-4、IL-10和IL-17水平明顯降低，而干擾素-γ（IFN-γ）和IL-18水平明顯增高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組上述血清學(xué)指標(biāo)改善后水平明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 潤燥止癢膠囊聯(lián)合鹽酸奧洛他定片治療慢性蕁麻疹可有效改善患者臨床癥狀，降低機(jī)體炎癥反應(yīng)，提高患者生活質(zhì)量。

Objective To investigate the clinical effect of Runzao Zhiyang Capsules combined with olopatadine in treatment of chronic urticaria. Methods Patients (84 cases) with chronic urticaria in Chinese PLA No.195 Hospital from February 2017 to August 2017 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were po administered with Olopatadine Hydrochloride Tablets, 5 mg/time, twice daily. Patients in the treatment group were po administered with Runzao Zhiyang Capsules on the basis of the control group, 2 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptoms and DLQI scores, the serological indexes in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the control group was 78.57%, which was significantly lower than 95.24% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the clinical symptoms and DLQI scores in two groups were significantly decreased, and there were differences in the same group (P < 0.05). And these scores in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the serum IL-4, IL-10, and IL-17 levels in two groups were significantly decreased, but IFN-γ and IL-18 were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Runzao Zhiyang Capsules combined with olopatadine in treatment of chronic urticaria can effectively improve the clinical symptoms, reduce inflammation, and improve the quality of life.